Category: 3. Business

  • Work-Life Balance Tops Pay As Employees Re-Evaluate Priorities, But This Is ‘Mind-Boggling’ To Some CEOs

    Work-Life Balance Tops Pay As Employees Re-Evaluate Priorities, But This Is ‘Mind-Boggling’ To Some CEOs

    As Americans rethink what they want out of their careers, work-life balance is taking center stage. For the first time since Randstad began tracking employment trends 22 years ago, balance has surpassed pay as the top motivator for workers considering a job.

    But while many employees see this shift as long overdue, some high-profile CEOs say the idea of achieving big ambitions without long hours simply doesn’t add up.

    According to Randstad’s Workmonitor 2025 report, 83% of workers now rank work-life balance as their highest priority — slightly edging out both job security and pay. This shift is part of a broader change in expectations: workers want jobs that fit around their lives, not the other way around.

    Don’t Miss:

    Randstad says that employees are increasingly looking for workplaces that reflect their values and support their ambitions. Nearly half say they wouldn’t accept a job with a company whose social or environmental values don’t align with their own — up sharply from 38% last year. And more workers are willing to walk away altogether, with 31% having quit due to limited career advancement.

    Younger generations have been especially vocal about challenging the traditional grind. For Gen Z, 74% list work-life balance as a top consideration, compared with 68% who prioritize pay, according to the report. Many even rank mental health support above compensation.

    This group also places a premium on flexibility. A LinkedIn report found that around 38% of Gen Z and millennial workers would take a pay cut for more remote or hybrid options.

    Still, this mindset isn’t limited to younger employees. Randstad reports baby boomers also rate work-life balance (85%) and pay (87%) as top priorities, showing that interest in sustainable work schedules spans generations.

    Trending: 7 Million Gamers Already Trust Gameflip With Their Digital Assets — Now You Can Own a Stake in the Platform

    Despite broad agreement among workers, executives remain divided on whether meaningful balance can coexist with high achievement.

    Netflix (NASDAQ:NFLX)  co-founder Marc Randolph is one leader who advocates for clear boundaries. Throughout his career, he kept Tuesday nights strictly free from work — no meetings, no last-minute calls. “Those Tuesday nights kept me sane. And they put the rest of my work in perspective,” he wrote in a LinkedIn post.

    JPMorgan Chase (NYSES: JPM) CEO Jamie Dimon has shared similar advice, telling students at the Georgetown Psaros Center for Financial Markets and Policy last year that protecting mental, physical, and spiritual health is essential to long-term success.

    But not all executives see balance and ambition as compatible. Some of the tech world’s most influential leaders — including Google co-founder Sergey Brin and Scale AI co-founder  Lucy Guo — have pushed back on the idea of clocking in at 9 a.m. and out at 5 p.m, according to Fortune.

    See Also: GM-Backed EnergyX Is Solving the Lithium Supply Crisis — Invest Before They Scale Global Production

    Andrew Feldman, CEO of AI chipmaker Cerebras, was even more direct. “This notion that somehow you can achieve greatness, you can build something extraordinary by working 38 hours a week and having work-life balance — that is mind-boggling to me,” he said on a recent episode of the “20VC” podcast. “It’s not true in any part of life.”

    As workers weigh not only income but values, flexibility, and well-being, employers face a growing challenge: adapting to expectations that are broader and more personal than ever.

    The data suggests this shift won’t fade anytime soon. With talent shortages in many industries and more employees willing to leave roles that don’t meet their needs, organizations may find that supporting balance isn’t just a perk; it’s a competitive advantage.

    Read Next: Wall Street’s $12B Real Estate Manager Is Opening Its Doors to Individual Investors — Without the Crowdfunding Middlemen

    Image: Shutterstock

    Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.

    Get the latest stock analysis from Benzinga:

    This article Work-Life Balance Tops Pay As Employees Re-Evaluate Priorities, But This Is ‘Mind-Boggling’ To Some CEOs originally appeared on Benzinga.com

    © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Continue Reading

  • Former Federal Reserve Bank Executive Reveals The $1 Trick That Turns ‘Someday’ Investors Into ‘Today’ Investors

    Former Federal Reserve Bank Executive Reveals The $1 Trick That Turns ‘Someday’ Investors Into ‘Today’ Investors

    One dollar is all it takes to transform someone from a perpetual “someday” investor into an actual market participant, according to a former Federal Reserve Bank of Boston executive who spent years inside America’s most powerful financial institutions before joining the retail investing wave.

    Kristin Kanders, head of marketing and engagement at the Plynk app, a retail brokerage app designed to simplify investing, believes the barrier keeping millions of Americans out of the stock market has nothing to do with money. The real obstacle is psychological.

    After serving as director of strategy and innovation at the Boston Fed and head of transformation engagement and communications at State Street, Kanders now leads a team focused on turning big ideas into real-world solutions for investors of all experience levels.

    Don’t Miss:

    • The AI Marketing Platform Backed by Insiders from Google, Meta, and Amazon — Invest at $0.85/Share

    • Missed Tesla? EnergyX Is Tackling the Next $200 Billion Opportunity — Lithium

    The problem with modern investing apps has nothing to do with features or functionality, Kanders said in an exclusive interview with Benzinga. The problem is much deeper. “Access alone doesn’t equal empowerment,” Kanders said. “I believe the real shift in consumer psychology needs to be from transactional thinking to ownership thinking.”

    Kanders pointed out that most retail investors approach the market with the wrong mentality entirely. “Right now, many retail investors see investing as a quick trade or a way to ‘play the market,’” she said. “It’s no wonder then that the majority of people in the U.S. feel anxious about their personal finances.”

    Kanders said genuine confidence grows when people move away from chasing quick trades and instead form a long-range relationship with their financial goals. She described empowerment as the point where investors feel steady in their decisions because they understand the purpose behind them, not just the mechanics.

    The transition requires more than just access to trading platforms. “The change isn’t just about giving tools; it’s about building confidence so investors believe they can shape outcomes, not just chase them,” she said. “In short, having a growth mindset matters. And that’s why we provide lots of tools to learn as you go.”

    Starting with one dollar might sound like a gimmick. Kanders insists the psychological impact cannot be overstated. “For many people, it’s not the $100 or $1,000 that holds them back from investing,” she said. “The psychological weight of ‘I’m not ready,’ ‘I don’t know enough,’ or ‘I’m not the investing type’ is often heavier than any dollar amount.”

    The magic happens when someone makes that first transaction, Kanders said. “Removing the financial barrier unlocks more than just access, it unlocks a starting point,” she told Benzinga. “When someone invests $1, they become an ‘investor.’ That shift, even if tiny, rewires self-perception. It creates momentum. It builds confidence. It turns ‘someday’ into ‘today.’”

    Plynk launched a feature called Steady Start built around this concept. Users pick a security, start with $1, and each week their investment increases by $1 for 52 weeks, Kanders said. “We’re turning ‘I’ll start investing later’ into ‘I’m already building something.’”

    The Plynk app’s core promise centers on “invest with confidence,” not “get rich” or “beat the market.”

    “Our messaging stays authentic because we frame investing as a marathon, not a sprint,” Kanders told Benzinga. “Market downturns are inevitable, so we focus on education and transparency: helping users understand why volatility happens and how long-term strategies historically outperform short-term reactions.”

    “Confidence isn’t about avoiding losses, it’s about knowing what to do when they happen,” Kanders added. “Instead of promising to beat the market, we give them tools and insights to make informed decisions, even in tough times.”

    Kanders pointed to simulated trading as one of the platform’s core teaching tools. She said the feature offers a real-market environment where users can practice strategies, build confidence, and learn from outcomes without putting actual money at risk.

    Kanders acknowledged that every fintech platform sees users take losses and said Plynk focuses on helping investors stay mindful of their risk limits. She added that markets move for many reasons and emphasized the value of regularly checking personal risk appetite. “It is important to continually evaluate risk appetite in investments to make sure you’re not ‘biting off more than you can chew,’” Kanders said.

    Trending: 7 Million Gamers Already Trust Gameflip With Their Digital Assets — Now You Can Own a Stake in the Platform

    Kanders addressed whether Plynk intentionally designs for human psychology, nudging people toward better decisions or respecting their autonomy even when users make suboptimal choices.

    “The Plynk app provides a self-directed investing experience—so we do not nudge people one way or another,” she said. “Instead, our education and tools are designed to help people make the best decisions for themselves. We aim to meet people where they are and empower them to grow.”

    She compared the app to a financial co-pilot. “Think of the Plynk app as a financial co-pilot: we don’t take the wheel, but we give users a better rearview mirror and tools that help users spot their blind spots, map their path, and adjust course,” Kanders told Benzinga.

    Kanders said the app introduced new features in 2025 that follow this philosophy, including a “what-if” tool that lets users explore virtual portfolios. These scenario-based views help people see how different choices might have played out, reinforcing the long-term benefits of staying invested rather than waiting on the sidelines.

    The goal is to help users visualize consequences. “What if they started investing a year ago? What if they skipped the impulse trade?” Kanders said.

    When asked what about the fintech industry gets sanitized in marketing, Kanders pulled no punches. “Well, a lot of marketing that I see doesn’t look that sanitized. It’s sensationalized!” she told Benzinga. “But we definitely don’t do that at Plynk. We stick to the ‘underpromise, overdeliver’ philosophy.”

    The often-overlooked factor most fintech companies avoid discussing centers on market complexity. “While we aim to make the process of investing simple, the reality is that markets are messy,” Kanders said. “It takes tenacity and confidence to get through downtimes, and we know it’s not effortless.”

    The phrase “democratizing finance” has become nearly universal in fintech marketing. Kanders outlined what the phrase means to Plynk and how the company ensures the concept translates into action rather than empty language.

    “The core meaning behind ‘democratizing finance’ is simple: accessibility,” Kanders told Benzinga. “It’s about knocking down the barriers that made investing hard to break into, whether it’s because of minimum asset thresholds, the jargon surrounding the industry, or the ability to engage on a mobile device.”

    Plynk brings this philosophy to life through community-focused outreach, Kanders said. The team connects with people in the spaces they already spend time in, including finance creators, young women, service members, and veterans at events and conferences. She added that feedback from these groups informs new app features and directs product decisions.

    “Ultimately, democratizing finance means making it possible for more people to participate in the market because we’ve given them the knowledge and confidence to do so,” Kanders said.

    The military community represents a strategic focus for Plynk. Kanders said the unique financial challenges veterans and service members face that traditional investing apps completely miss.

    “We believe in the purpose of what we are doing and feel it is an honorable mission,” she told Benzinga. “We were moved by the challenges military veterans and service members face and felt there was a great fit with the Plynk app being able to be an ally for the community.”

    Kanders said veterans shared strong concerns about financial tools that feel inaccessible or out of step with their needs. These conversations motivated the team to create Plynk Serve: Military, a tailored offering designed in response to complaints about complicated language and hard-to-navigate app interfaces.

    The sentiment Kanders hears most frequently from this community reveals a deeper problem. “We hear this often: ‘Investing isn’t for me,’” she said. “Not because of ability, but because the investing world can feel unwelcoming, full of jargon and assumptions that you already know the playbook. It’s easy to feel like an outsider. The Plynk app is for anyone who has ever felt overlooked or intimidated by the world of investing, and a large part of this community fits that demographic.”

    Kanders said the move from military service to civilian life often brings unfamiliar financial decisions and less structure than veterans are used to. This change can feel overwhelming, with most apps offering either rigid paths or too many choices with no clear guidance. She added that Plynk built Plynk Serve: Military to offer a resource that supports this transition in a more practical way.

    See Also: Earn While You Scroll: The Deloitte-Ranked #1 Software Company Growing 32,481% Is Opening Its $0.50/Share Round to Accredited Investors.

    Technology is changing not just access to investing, but investor behavior itself, and Kanders identified several major trends in how new investors make decisions, manage risk, and seek advice.

    “Social media is now a primary source of financial advice for younger investors: 76% of Gen Z turn to TikTok, Instagram, and Reddit for investing tips, compared to just 18% of older investors,” she told Benzinga.

    “This creates a fast-paced, community-driven dynamic where [fear of missing out] and viral trends influence risk-taking,” Kanders added. “Trading frequency is higher among social-media-driven investors, and speculative assets like crypto and meme stocks dominate.”

    Furthermore, artificial intelligence represents the biggest turning point coming to personal finance, Kanders said. “It makes sense to me that AI is all over the headlines. It has the potential to be a game-changer for helping people manage their finances, either directly or indirectly. We’re being brought into a new era of personalization because of AI,” she said.

    When asked what single skill retail investors should develop before ever investing, Kanders gave an answer that had nothing to do with technical analysis or financial statements.

    “Curiosity,” she said. “Approaching the market with curiosity, ambition, and caution is what leads to a successful investing journey. When you’re genuinely curious, you’re more receptive to learning, actively seeking to grow your financial literacy and investing knowledge. This practice of curiosity is often what leads to a stronger sense of confidence when it comes to investing.”

    Looking five years into the future, Kanders predicted completely normal investing behaviors that would shock someone from 2020. “In five years’ time I think we’ll have new ways to ‘see’ and explore our personal portfolios that feel more natural, intuitive and immersive than today’s pie chart world,” she said. “Picture more interactive experiences and less finance spreadsheet.”

    Kanders added that the company had already begun experimenting with what the next chapter of investing could look like. This led to the launch of Plynk Spatial, an initiative aimed at exploring more immersive ways to engage with markets.

    For Plynk, success gets measured in user growth. Kanders detailed how she personally defines success and when she’ll know Plynk has accomplished its mission. “True success lies in our ability to make financial confidence accessible to everyone,” she told Benzinga. “If we hit a hundred million users, but none of them feel confident or informed about their money choices, I’d consider that a failure.”

    All investments involve risk, including the possible risk of loss.

    Simulated trading is for informational purposes only. Past performance does not guarantee future results; actual performance returns will vary.

    The projections or other information generated by the Virtual Portfolio regarding the virtual investment outcomes are hypothetical in nature, do not reflect actual investment results and are not guarantees of future results.

    DBS does not provide individualized investment advice or recommendations. All general educational resources that DBS provides are available to help users make educated investment decisions on the mobile app. None of the general education tools or information we provide should be viewed as individualized recommendations to buy, sell, or hold any investment

    The Plynk app is supported by a team of Digital Brokerage Services LLC associates. Brokerage services are offered through the Plynk application only by Digital Brokerage Services LLC.. Plynk marks are the property of FMR LLC; third-party marks are the property of their respective owners. 1236494.1.0

    Read Next: Americans With a Financial Plan Can 4X Their Wealth — Get Your Personalized Plan from a CFP Pro

    Image: Shutterstock

    Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.

    Get the latest stock analysis from Benzinga:

    This article EXCLUSIVE: Former Federal Reserve Bank Executive Reveals The $1 Trick That Turns ‘Someday’ Investors Into ‘Today’ Investors originally appeared on Benzinga.com

    © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Continue Reading

  • Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

    Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

    The all-oral combination comprised of revumenib (Revuforj) plus decitabine/cedazuridine and venetoclax (Venclexta; SAVE regimen) elicited responses in patients with newly diagnosed acute myeloid leukemia (AML) although a concern for myelosuppression was reported, according to data from the phase 1/2 SAVE trial (NCT05360160).1

    The findings which were presented at the 2025 ASH Annual Meeting & Exposition showed that the regimen in patients with newly diagnosed with AML (n = 21) induced an objective response rate (ORR) of 86%, which comprised a complete remission (CR)/CR with partial hematologic recovery (CR/CRh) rate of 81% and a CR with incomplete platelet count recovery (CRp) rate of 5%; the CR rate was 76% and the CRh rate was 5%. All patients who attained composite CR achieved minimal residual disease (MRD) negativity at a sensitivity of 10-4 by multiparameter flow cytometry. Two early deaths occurred, and 1 patient withdrew consent and was not response evaluable.

    At a median follow-up of 9 months, the median duration of response (DOR) was not reached (NR) in those attaining CR or CRh, and the 12-month DOR rate was 70% (95% CI, 46%-100%). Moreover, the median overall survival (OS) was NR, with a 12-month OS rate of 57% (95% CI, 36%-90%); the median event-free survival (EFS) was also NR, with a 12-month EFS rate of 50% (95% CI, 29%-85%).

    In terms of safety, the most common any-grade adverse effects (AEs) were vomiting (67%), elevated aspartate and alanine aminotransferase levels (62%), nausea (57%), and electrolyte disturbances. The most frequent grade 3 or higher AEs were febrile neutropenia (48%), thrombocytopenia (33%), neutropenia (24%), bacteremia (19%), and site-specific infections (lung, 14%; skin, 14%). Three grade 5 events were reported in the form of bacteremia (n = 2) and bronchopulmonary hemorrhage (n = 1). Any-grade differentiation syndrome (DS) occurred in 19% of patients, with 2 cases grade 3 or higher; all cases resolved with steroids.

    “The all-oral combination of revumenib, decitabine/cedazuridine and venetoclax shows good activity in newly diagnosed AML with NPM1 mutations or KMT2A rearrangements. Response and MRD-negative rates were high, although the cohort size is small and the follow-up period is short,” Wei-Ying Jen, MA, BMBch, M Med, FRCPath said. “We recommend empiric, high-dose steroids at the earliest suspicion of differentiation syndrome, even within the context of combination therapy. There is concern for myelosuppression, as evidenced by the rate of infectious complications; this highlights the need to optimize menin inhibitor combinations to improve the overall risk-benefit profile—especially in NPM1-mutated AML.”

    Jen is an assistant professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, in Houston, Texas.

    How are menin inhibitors like revumenib being evaluated in leukemias?

    SAVE Regimen: Revumenib Plus Decitabine/Cedazuridine and Venetoclax in AML

    • The all-oral SAVE regimen produced high response and MRD negativity rates in patients with newly diagnosed, menin-susceptible AML.
    • Remissions appeared durable at early follow-up, with median OS, EFS, and DOR not yet reached.
    • Myelosuppression and infections were common, underscoring the need to refine menin-inhibitor combinations to improve safety.

    “Menin is a scaffold protein which regulates gene expression. The interaction of menin and KMT2A is a critical dependency in KMT2A-rearranged or NPM1-mutated acute leukemias; this leads to aberrant gene expression and leukemogenesis,” Jen explained. “Revumenib is a potent and selective small molecule inhibitor of this interaction.”

    In November 2024, the FDA cleared revumenib for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory AML and a KMT2A translocation.2 The following year, in October 2025, the regulatory agency has approved the drug for use in adult and pediatric patients at least 1 year of age with relapsed or refractory AML and a susceptible NPM1 mutation who do not have satisfactory alternative treatment options.3

    What was the rationale for the SAVE combination?

    Jen reported that single-agent revumenib has elicited ORRs ranging from 43% to 60% in those with relapsed/refractory AML and KMT2A rearrangement or NPM1 mutation, with CR/CRh rates ranging from 21% to 30%, and DORs ranging from approximately 4 months to 6 months.1 “However, responses can be short lived; therefore, there is a need to improve response rates and decrease the risk of relapse with rational combination strategies,” Jen said.

    Although hypomethylating agents in combination with venetoclax is standard treatment for patients who are older or unfit with AML and has improved outcomes, relapse is inevitable for most patients, Jen noted. Preclinical data have indicated that BCL-2 and menin inhibition improved survival outcomes.

    What was the design of the SAVE trial with the revumenib regimen?

    The phase 1/2 study enrolled patients with relapsed or refractory AML or mixed phenotype acute leukemia who were at least 12 years old. Patients were required to have an ECOG performance status ranging from 0 to 2 and have acceptable organ function. Additionally, the frontline phase 2 cohort included patients who were not eligible for intensive chemotherapy whose tumors harbored KMT2A rearrangement, NPM1 mutation, or NUP98 rearrangement.

    The phase 1 portion leveraged a 3+3 dose-escalation design. Revumenib was given at 110 mg plus CYP3A4 inhibition or 160 mg without CYP3A4 inhibition (DL 0) or 160 mg plus CYP3A4 inhibition or 270 mg without CYP3A4 inhibition (DL 1). “The recommended phase 2 dose [RP2D] of revumenib was identified as 160 mg twice daily with strong CYP3A4 inhibitors, or 270 mg twice daily with strong CYP3A4 inhibitors,” Jen noted.

    Revumenib was administered on days 1 to 28. Decitabine/cedazuridine was given on days 1 to 5, and venetoclax was given at a target dose of 400 mg with ramp up on days 1 to 14.

    The primary objective for phase 1 in patients with relapsed/refractory disease was to evaluate safety and identify the maximum tolerated dose and RP2D; for phase 2, it was to evaluate the efficacy of the regimen in those with frontline and relapsed/refractory disease. Secondary objectives for the phase 2 portion looked at OS, relapse-free survival, complete response duration, and MRD. Exploratory objectives focused on MRD at 10-5 and resistance.

    During the first cycle, day 14 bone marrow was performed. “If bone marrow blasts were less than 5%, revumenib was held after day 21,” Jen noted. “Revumenib monotherapy was resumed as maintenance post-transplant for a planned duration of one year.”

    At the meeting, Jen shared the outcomes of the newly diagnosed cohort of the study. In all patients, the median age was 70 years (range, 60-83) with 52% aged 70 years or older. Most patients were female (71%) and almost one-fourth had secondary AML (24%). In terms of comutations, 19% of patients had NRAS/KRAS, 19% had FLT3 (ITD, 5%; TKD, 14%), IDH1/2 (19%), or MDS-associated mutations in genes like ASCL1, BCOR, EZH2, SF3B1, STAG2, U2AF1, ZRSR2, and RUNX1 (43%).

    What was the efficacy of the SAVE regimen according to genotype?

    In those with NPM1 mutations (n = 14), the ORR with the SAVE regimen was 86%, which comprised a CR/CRh rate of 79%; the CR rate was 71% and the CRh rate was 7%. The CRp rate was 7% in this group. Most patients (86%) were MRD negative 10-4 by multicolor flow cytometry. Two patients (10%) experienced early death. The median DOR was NR, and the 12-month DOR rate was 71% (95% CI, 43%-100%). The median OS was also NR, with a 12-month OS rate of 53% (95% CI, 29%-97%).

    In patients with KMT2A rearrangements (n = 7) the SAVE regimen induced an ORR of 86%, which comprised a CR/CRh rate of 86%; the CR rate was 86%. Fourteen percent of patients were not evaluable. Again, 86% of patients achieved MRD negativity 10-4. The median DOR was NR, with a 12-month DOR rate of 80% (95% CI, 52%-100%). The median OS was also NR, with a 12-month OS rate of 69% (95% CI, 40%-100%).

    What NPM1 MRD trends were observed?

    Jen reported that most patients achieved MRD negativity at the end of cycle 2, with clearance rates improving over time. She added that two patients did not have NPM1 MRD clearance and went on to relapse. In those who achieved a CR/CRh, the median DOR was NR. “An estimated 70% of patients are still in remission at 1 year,” Jen said. “At a median follow-up of 9 months, the median OS and EFS have not been reached.”

    What was learned in terms of resistance mechanisms?

    Jen noted that a ddPCR assay was designed to identify eight MEN1 point mutations, which confer resistance to revumenib. “Synthetic gBlocks, representing each mutation and wild-type controls, were generated for assay development and optimization. Of note, there was false-positive detection of some variants at a low mutation burden, likely corresponding to binding of the wild-type MEN1 gene.”

    She added that at the time of relapse, MEN1 mutation testing was done for two of the three cases of relapse. One MEN1 M327B mutation was detected with a variant allele frequency of 17%. “This mutation has been described in vivo and in vitro with exposure to revumenib as well as other menin inhibitors,” she noted, adding that the emergent MEN1 mutation suggests that the combination regimen may not fully address this mechanism of relapse and that there are likely other resistance mechanisms inherent to the combination that need to be further examined.

    Disclosures: Jen did not disclose any financial relationships.

    References

    1. Jen W-Y, DiNardo CD, Short NJ, et al. Phase II study of the all-oral combination of revumenib with decitabine/cedazuridine and venetoclax (SAVE) in newly diagnosed AML. Presented at: 2025 ASH Annual Meeting; December 6-9, 2025; Orlando, FL. Abstract #47.
    2. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. FDA. November 15, 2024. Accessed December 7, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation
    3. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. FDA. October 24, 2025. Accessed December 7, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation

    Continue Reading

  • Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures | NeurologyLive

    Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures | NeurologyLive

    A phase 2 multicenter, randomized, open-label, active comparator (AC) trial, coined SP0968 (NCT04519645), revealed positive efficacy, safety, and pharmacokinetic data for investigational lacosamide (LMC) in treating neonates with repeated electroencephalographic neonatal seizures (ENS).

    Findings from the study indicated that LCM both reduced seizure burden and was well tolerated by patients. The study also found that despite the increased LCM exposure observed in neonates, their serum concentrations remained broadly consistent with adult levels at a dose of 400 mg/day in the absence of inducers.1

    Presented at the 2025 American Epilepsy Society (AES) Annual Meeting, held December 5-9, in Atlanta Georgia, the study randomized participants 1:1 to either LCM 15 mg/kg/day (5 mg/kg every 8-hours via 30-min intravenous infusions) or AC, selected and dosed according to local standard of care and treatment guidelines. The primary outcome of the study was the change in seizure burden, measured as minutes of electrographic neonatal seizures (ENS) per hour, from baseline video electroencephalography (vEEG; −2 to 0 hours before treatment) to the evaluation period vEEG (1 to 3 hours after treatment). Secondary outcomes included the incidence of treatment-emergent adverse events (TEAEs) and mean serum concentrations of LCM.

    Rescue medication (RM) was permitted when needed; however, participants who received RM within 3 hours after the first dose were excluded from the primary efficacy analysis and were considered non-responders for responder outcomes. Patients who benefited from their randomized treatment were eligible to continue in an extension period of up to 28 days postnatal age.

    Led by Wendy Waldman Zadeh, MD, a neurologist at Broadlawns Medical Center in Des Moines, Iowa, the study included 26 patients who received at least one dose of study treatment: 14 were assigned to LCM and 12 to the AC (mean PNA 3.7 days; 53.8% female; Safety Set [SS]). Among patients who did not receive rescue medication (RM)(LCM n=11; AC n=9), the median reduction in seizure burden from baseline to the evaluation period was 4.74 min/h (range: −0.9 to 22.0) with LCM and 2.51 min/h (range: −32.4 to 19.6) with AC. In the LCM and AC groups, 9/15 (60.0%) and 6/9 (66.7%) were responders; 9/15 (60.0%) and 4/9 (44.4%) achieved ≥80% response; and 9/14 (64.3%) and 6/8 (75.0%) were seizure-free at 24 hours, respectively.

    Regarding adverse events, 9 patients (64.3%) in the LCM group experienced 21 TEAEs, 1 patient (7.1%) had 2 drug-related TEAEs, and 2 patients (14.3%) had a single serious TEAE each. In the AC group, 5 (41.7%) patients had 21 TEAEs. Furthermore, the geometric mean serum concentration of LCM was 7.003 μg/mL at 30–90 min (n = 11) and 5.949 μg/mL at 6–8 h (n = 12) after start of first infusion (Pharmacokinetic Per-Protocol Set).

    Read More: Lacosamide Provides Benefit as Second-Line Treatment for Refractory Trigeminal Neuralgia

    Lacosamide was previously studied in a retrospective descriptive cohort trial. Findings from that trial demonstrated that the antiepileptic agent can be a valid alternative for patients with trigeminal neuralgia (TN) who fail first-line treatments, apart from its potential previously reported use as an intravenous rescue medication.2

    Data were collected on 86 patients with refractory TN who has previously tried the treatments carbamazepine or oxcarbazepine. More than half (54%) of the cohort continued on either of those therapies as a concomitant treatment, and 14% were treated with lacosamide as monotherapy.

    At the conclusion of the analysis, two-thirds (66%) of patients achieved pain relief from their condition. AEs, found in 33% of the cohort, were mild in all cases. During the follow-up, 44% (n = 38) of patients suspended lacosamide treatment, with reasons that included clinical improvement (34%; n = 13), inefficacy (45%; n = 17), and intolerance (21%; n = 8). Investigators found no statistically significant differences in demographical and clinical data between responders and nonresponders, except for bilateral pain distribution, for which the 3 patients were all nonresponders.

    REFERENCES
    1. Moseley B, Cleveland J, Krauwinkel W, et al. Efficacy, Safety, and Pharmacokinetics of Lacosamide in NeonatesWith Seizures: Results of a Phase 2/3, Open-Label, Randomized, Active Comparator Trial . Presented at 2025 American Epilepsy Society Annual Meeting; December 5-9, Atlanta, Georgia.
    2. Munoz-Vendrell A, Tena-Cucala R, Campoy S, et al. Oral lacosamide for the treatment of refractory trigeminal neuralgia: a retrospective analysis of 86 cases. Headache. Published online April 10, 2023. doi:10.1111/head.14505

    Continue Reading

  • Has Klarna’s 2025 Share Price Slide Reset Expectations After BNPL Expansion Push?

    Has Klarna’s 2025 Share Price Slide Reset Expectations After BNPL Expansion Push?

    • If you are wondering whether Klarna Group is a bargain or a value trap at today’s price, you are not alone. This article unpacks what the current share price really implies.

    • After sliding 0.4% over the last week and 13.4% in the last month, the stock is now down 31.6% year to date. This move has sharply reset expectations and risk perceptions.

    • Recent headlines have focused on Klarna’s push to expand its buy now, pay later footprint in key markets and deepen partnerships with major retailers, which many investors view as important for reigniting growth. At the same time, regulators and industry commentators have been scrutinizing the BNPL model more closely, adding a layer of uncertainty that appears to be influencing recent price action.

    • Right now Klarna Group scores just 1 out of 6 on our valuation checks. We will break down what that means across different valuation methods and then finish by looking at a more intuitive way to think about what the market is really pricing in.

    Klarna Group scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

    The Excess Returns model asks a simple question: does Klarna earn enough on its equity to justify its current valuation once the true cost of that equity is accounted for? It looks at what shareholders put into the business versus what they are getting back over time.

    For Klarna, the starting point is a Book Value of $6.49 per share and a Stable EPS estimate of $0.27 per share, based on weighted future Return on Equity forecasts from 8 analysts. Against this, the model applies a Cost of Equity of $0.67 per share, implying an Excess Return of $-0.39 per share, meaning Klarna is expected to earn less than its equity cost on a per share basis.

    The average Return on Equity is just 3.37%, while the Stable Book Value is projected to rise to $8.09 per share, based on estimates from 5 analysts. When these modest returns are projected forward, the Excess Returns valuation implies an intrinsic value near zero, making the shares look roughly 18179.1% overvalued at today’s price.

    Result: OVERVALUED

    Our Excess Returns analysis suggests Klarna Group may be overvalued by 18179.1%. Discover 908 undervalued stocks or create your own screener to find better value opportunities.

    KLAR Discounted Cash Flow as at Dec 2025

    Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Klarna Group.

    For companies like Klarna that are still normalizing profitability, the price to sales ratio is often the cleanest way to compare value, because it looks at what investors are paying for each dollar of revenue rather than volatile earnings.

    Continue Reading

  • How Analysts See Innovative Aerosystems Entering a New Growth Era and Shifting Its Story

    How Analysts See Innovative Aerosystems Entering a New Growth Era and Shifting Its Story

    Innovative Aerosystems has seen its fair value estimate climb from roughly $10.70 to about $16.47 per share, even as analysts dial back their revenue growth outlook from around 16.8% to about 9.3% annually. Bulls argue that a more visible, retrofit driven demand pipeline and a sharpened strategic focus justify the higher valuation, despite more conservative top line assumptions and a modest uptick in the discount rate from roughly 6.4% to about 7.8%. Read on to see how you can stay ahead of these shifting expectations and keep updated on the evolving narrative around the stock.

    Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Innovative Aerosystems.

    🐂 Bullish Takeaways

    • Northland analyst Robert Brooks has initiated coverage of Innovative Aerosystems with an Outperform rating and a $16.50 price target, effectively endorsing the recent step up in the stock’s fair value.

    • Northland highlights the company’s focus on the retrofit market and domestic manufacturing as key advantages that align with the secular trend of aging airplane fleets, supporting a durable growth runway.

    • The analyst points to recent niche product acquisitions and a revamped management team as evidence of improving execution quality and strategic focus, framing Innovative Aerosystems as entering a “new growth era.”

    • Even with the bullish stance, Northland’s target implies that a meaningful portion of the growth story is already reflected in the share price, which may limit upside if execution or demand trends disappoint.

    🐻 Bearish Takeaways

    • Beyond Northland’s initiation, there is limited published dissenting research. However, the single $16.50 target suggests that, at current levels, investors have to assume continued flawless execution and sustained retrofit demand, leaving less room for error on valuation and near term results.

    Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

    NasdaqGS:ISSC Community Fair Values as at Dec 2025
    • On October 14, 2025, the company rebranded from Innovative Solutions and Support to Innovative Aerosystems, a move intended to better reflect its core focus on aircraft retrofit programs and integrated avionics systems.

    • The rebrand is accompanied by updated marketing materials and customer messaging that emphasize lifecycle support, cockpit modernization, and fleet efficiency solutions for commercial and defense operators.

    • Innovative Aerosystems has been added to the S&P Global BMI Index, a change that may boost trading liquidity and attract additional institutional investors that benchmark to or track the index.

    • Index inclusion is expected to support demand for the shares over time, particularly from passive and rules based strategies that allocate capital according to index membership and free float weighting.

    Continue Reading

  • Exploring 3 High Growth Tech Stocks in Australia

    Exploring 3 High Growth Tech Stocks in Australia

    As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.

    Name

    Revenue Growth

    Earnings Growth

    Growth Rating

    Pureprofile

    10.51%

    37.56%

    ★★★★★☆

    Pro Medicus

    19.70%

    21.18%

    ★★★★★☆

    Kinatico

    13.27%

    42.29%

    ★★★★☆☆

    Immutep

    104.12%

    46.46%

    ★★★★★☆

    Clinuvel Pharmaceuticals

    22.02%

    23.88%

    ★★★★★☆

    BlinkLab

    104.90%

    101.40%

    ★★★★★★

    Wrkr

    52.49%

    88.00%

    ★★★★★★

    Artrya

    50.54%

    61.25%

    ★★★★★☆

    PYC Therapeutics

    10.34%

    24.39%

    ★★★★★☆

    FINEOS Corporation Holdings

    9.22%

    57.85%

    ★★★★☆☆

    Click here to see the full list of 23 stocks from our ASX High Growth Tech and AI Stocks screener.

    Let’s explore several standout options from the results in the screener.

    Simply Wall St Growth Rating: ★★★★★☆

    Overview: Artrya Limited is a medical technology company focused on developing and commercializing an artificial intelligence platform for detecting, diagnosing, and addressing coronary artery disease in Australia, with a market cap of A$545.39 million.

    Operations: The company generates revenue primarily from the development of AI-driven CCTA image analysis technology, amounting to A$0.03 million.

    Artrya, despite its current unprofitable status, is demonstrating robust potential with projected annual revenue growth at 50.5% and earnings expected to surge by 61.25% per year. This growth trajectory is significantly above the Australian market average of 6% for revenue and aligns with high-growth benchmarks in tech sectors globally. Recent strategic moves include a follow-on equity offering raising AUD 75 million, underscoring their aggressive expansion plans and commitment to scaling operations. These financial maneuvers are crucial as Artrya aims to transition from a small-scale operation into a profitable entity over the next three years, leveraging advancements in MedTech and digital health solutions showcased in recent high-profile conferences like the CG MedTech Forum in New York.

    ASX:AYA Earnings and Revenue Growth as at Dec 2025

    Simply Wall St Growth Rating: ★★★★☆☆

    Overview: Cogstate Limited is a neuroscience solutions company focused on developing and commercializing digital brain health assessments globally, with a market capitalization of A$435.93 million.

    Continue Reading

  • Ted Sarandos Spoke With Donald Trump Ahead of Warner Bros. Deal

    Ted Sarandos Spoke With Donald Trump Ahead of Warner Bros. Deal

    Netflix taking pole position to win the race for Warner Bros. Discovery sent shockwaves through Hollywood, partially because it was presumed that Paramount Skydance CEO David Ellison had the support of President Donald Trump.

    Now multiple sources tell The Hollywood Reporter that Netflix may also have received some sort of blessing by Trump, or at least his ear. Insiders says that Netflix co-CEO Ted Sarandos spoke with the President in the last couple of weeks in a confab that lasted about two hours.

    “We do not discuss private meetings that may or may not have occurred,” a White House official told THR. Netflix did not respond to multiple requests for comment on Friday and over the weekend.

    While sources did not know what the two men discussed, it does seem to point to an outcome that led to Netflix feeling they had a clear enough runway to make a serious play for the historic studio. The streaming giant made the winning bid for the David Zaslav-led WBD, after offers that exceeded a $28 share price. That also meant agreeing to a $5.8 billion break up fee in case any deal falls through.

    The $82.7 billion deal will need to navigate a complex regulatory environment. Ellison and his executives believed that their deal would have an easier path to approval because of his ties, and that of his father, Larry Ellison, to the White House.

    If Sarandos made a pitch of his own, it may explain why Trump has been quiet on the deal, an unusual thing given how outspoken he is, particularly when it comes to major media stories.

    This would not be the first time Sarandos has sat down with Trump. The two men had a long dinner at Mar-a-Lago late last year, with the executive recalling that both First Lady Melania Trump and Barron Trump were Netflix fans. “We didn’t talk any shop,” Sarandos said in March.

    The more recent meeting, it seems, may have been a different story.

    Alex Weprin contributed to this report.

    Continue Reading

  • Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV – Medscape

    1. Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV  Medscape
    2. 52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV  AJMC
    3. Takeda (TAK): Promising Results for Rusfertide in Phase 3 VERIFY Study  GuruFocus
    4. Rusfertide Maintains Hematocrit Control Through 52 Weeks in VERIFY  HCPLive
    5. Rusfertide Continues to Show Strong Results for Polycythemia Vera  OncLive

    Continue Reading

  • Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

    Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

    Treatment with oral decitabine/cedazuridine (Inqovi) plus venetoclax (Venclexta) demonstrated high response activity and encouraging survival outcomes in patients with treatment-naive high-risk myelodysplastic syndromes (HR-MDS) or chronic myelomonocytic leukemia (CMML), according to results from a single-center phase 1/2 trial (NCT04655755).1

    The findings, presented at the 2025 ASH Annual Meeting and Exposition, showed that patients treated with the regimen (n = 69) achieved an overall response rate (ORR) of 91% per International Working Group (IWG) 2006 criteria, including a 45% complete remission (CR) rate and a 46% marrow CR (mCR) rate. Responses occurred early, with a median time to first response of 1 cycle (range, 1-3) and a median of 1 cycle to best response (range, 1-5). Patients received a median of 3 cycles (range, 1-25). Response classification using updated IWG 2023 and ELN 2022 criteria showed consistent depth of remission, with CR rates of 54% and 64%, respectively.

    The median overall survival (OS) for the full cohort reached 30 months, with 1- and 3-year OS rates of 68.8% and 40.7%, respectively. Median event-free survival (EFS) was 21.2 months, and the respective 1- and 3-year EFS rates were 60.7% and 32.6%. The median duration of response had not yet been reached (NR; 95% CI, 29-NR) at a median follow-up of 25 months (95% CI, 20-33).

    “Decitabine/cedazuridine with venetoclax is a feasible and safe combination for [patients with] HR-MDS and CMML,” lead study author Alex Bataller, MD, PhD, explained in his presentation of the data. “This combination is associated with a high ORR, [and responses] occur early in the treatment. The median OS of patients treated with decitabine/cedazuridine and venetoclax is 30 months, with a high proportion of patients undergoing hematopoietic stem cell transplantation [HSCT].”

    Bataller currently serves as an assistant professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

    A total of 38 patients proceeded to HSCT, with best responses comprising CR (n = 18), mCR (n = 19), and no response (n = 1). The median number of cycles prior to HSCT was 2 (range, 1-11). The median OS among the HSCT subgroup was NR, with 1- and 3-year OS rates of 70.4% and 50.7%, respectively. Six patients experienced disease progression or transformation to acute myeloid leukemia after HSCT, and 8 patients died in CR following HSCT.

    What was the design and patient enrolment criteria of the trial?

    The phase 1/2 clinical trial evaluating oral decitabine/cedazuridine with venetoclax in treatment-naive HR-MDS or CMML with excess blasts was designed as a single-center, open-label, dose-escalation and -expansion study. Patient enrollment at MD Anderson occurred between January 2021 and August 2024.2

    Eligible participants included individuals with previously untreated HR-MDS, defined by an International Prognostic Staging System (IPSS) intermediate-2 or high-risk category, or CMML with excess blasts. The study was structured in two phases.1 Phase 1 followed a standard 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Two dose levels were evaluated:

    • Dose level 0: decitabine/cedazuridine 35 mg/100 mg for 5 days plus venetoclax at 200 mg for 14 days (3 patients; no dose-limiting toxicities [DLTs] observed)
    • Dose level +1: decitabine/cedazuridine 35 mg/100 mg for 5 days plus venetoclax at 400 mg for 14 days (6 patients; no DLTs observed)

    Based on the absence of DLTs, dose level +1 was declared the RP2D.

    Phase 2 focused on assessing the efficacy of the RP2D, enrolling 60 additional patients treated with decitabine/cedazuridine 35 mg/100 mg for 5 days in combination with venetoclax at 400 mg for 14 days per cycle.

    In total, 74 patients were screened, and 69 were enrolled across both phases of the trial. The design supports a systematic evaluation of safety, tolerability, and preliminary efficacy of oral decitabine/cedazuridine combined with venetoclax.

    Which baseline clinical and molecular features characterized the study population?

    The median age at enrollment was 71 years (range, 21-94), and 71% of participants were male. Patients had a median bone marrow blast level of 12% (range, 6%-18%).

    Most patients carried a WHO 2016 diagnosis of MDS (86%), 13% had CMML, and 1 patient (1%) had atypical CML. Cytogenetic risk based on revised IPSS (IPSS-R) criteria further underscored the high-risk nature of the cohort: 39% had good-risk cytogenetics, 25% had intermediate risk, 12% had poor risk, and 25% had very poor risk. Therapy-related neoplasms were present in 22% of patients.

    Among those with MDS, IPSS-R risk classifications revealed that 59% were categorized as very high risk, 29% as high risk, and 12% as intermediate risk. Modified IPSS scoring aligned with this pattern, with 61% of patients classified as very high risk, 32% as high risk, and 7% as moderate-high risk.

    What was the safety profile observed with the combination of decitabine/cedazuridine and venetoclax in patients with high-risk MDS and CMML?

    Grade 3 adverse effects (AEs) occurred in 78% of patients; the rates of grade 4 and grade 5 AEs were 91% and 12%, respectively.

    Cytopenias were the most frequent high-grade toxicities. Grade 3 anemia occurred in 42% of patients, and grade 4 thrombocytopenia and neutropenia occurred in 65% and 71%, respectively. Febrile neutropenia was observed in 19% of patients. Serious infectious complications included grade 3 to 5 sepsis (12% grade 3; 3% grade 4; 6% grade 5) and pneumonia (9% grade 3; 3% grade 5). Additional infectious effects,such as viremia and skin infections occurred in 9% of patients each.

    “Infection prophylaxis and dose modifications are crucial to prevent excessive toxicity of this combination,” Bataller emphasized in his presentation. Seventy-five percent of patients underwent dose reductions during treatment.

    References

    1. Bataller A, Bouligny IM, Bazinet A, et al. Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk MDS or CMML: updates of a phase 1/2 clinical trial. Blood. 2025;146(suppl 1):237. doi:10.1182/blood-2025-237
    2. Venetoclax in combination with ASTX727 for the treatment of treatment-naive high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. ClinicalTrials.gov. Updated October 3, 2025. Accessed December 7, 2025. https://www.clinicaltrials.gov/study/NCT04655755

    Continue Reading